The race to win the first FDA nod for a classic psychedelic just got more interesting.
Compass Pathways has long been dubbed a leader of the field with its psilocybin-based candidate for treatment-resistant depression, considered the furthest along in development and predicted to become a blockbuster. But a dark horse recently sprang from the gate amid reports it beat Compass to the FDA with its psilocybin drug in depression.
Usona Institute, a nonprofit based in Wisconsin, has mostly kept a low profile about its investigational psilocybin candidate PSIL201. In March 2024, it launched its phase 3 trial for the treatment.
By April this year, the FDA said Usona’s treatment had secured a voucher for a speedier review under the Commissioner’s National Priority Voucher Program. Then earlier this month, a psychedelics industry analyst reported that Usona had already filed for FDA approval, a revelation that “caught many investors by surprise,” analysts at Stifel said in a note.
Usona hasn’t confirmed the FDA submission and in an emailed statement to PharmaVoice said it is not providing comments at this time. But the unconfirmed reports have already had a ripple effect.
Shares of Compass dropped by around 30% following the news. A week later, Compass announced it completed its own approval application. And now analysts are reconfiguring their picture of how the market could take shape.
Is Compass’ candidate, COMP360, still projected to become a blockbuster? Yes, multiple analysts predict. But will it rule the market alone? Here are the dynamics Compass will have to navigate.
The Usona factor
In most circumstances, it wouldn’t look like Usona has the goods to deliver on an FDA nod. Two pivotal trials are often used to support FDA approval, and Usona has yet to publicly release data from its phase 3 study. The trial's six-week double-blind treatment period might also fall short of the FDA's expectations for longer-term blinded data, Stifel analysts noted.
Then again, the regulatory landscape could come to Usona’s rescue.
“Beyond the broader push from HHS towards approval and access for psychedelic medicines, the current head of CDER, Michael Davis, was previously employed at Usona,” the analysts noted.
At the same time, Compass also has reasons to believe Usona won’t become a direct competitor even if its drug is approved.
Usona has been studying its candidate in major depressive disorder — a distinct indication from treatment-resistant depression.
Usona’s mission is also to supply psilocybin at a low cost that provides broad access. Compass, on the other hand, has won several patents for COMP360 and is more likely to price it in line with new branded drugs, according to Emma Wille, a senior analyst at Norstella’s Citeline.
In a market forecast published in August 2026, Wille estimated a drug list price of about $34,000 per year for COMP360, based on the Compass-guided estimate of two to four doses per year.
Although sales projections for COMP360 would depend on pricing and dosing frequency, Stifel analysts noted that it “only takes small penetration in this market to get close to blockbuster status.”
Analysts at RBC Capital Markets concurred with the blockbuster prediction, writing in a note that despite potential competitors, COMP360 could reach $1.9 billion in peak sales in treatment-resistant depression alone, and that there is “sufficient room for many new psychedelics” — a conclusion with which Wille agreed.
But getting payers on board and securing patient access will be key.
The pitch to payers
The terms of payer coverage will be one of the main hurdles, Wille said.
In order to get a new depression treatment approved, patients will likely have to try — and not respond to — at least a few generic medications. That dynamic is already intrinsic in the treatment-resistant depression indication Compass is targeting. It’s also the same treatment arena where Johnson & Johnson’s esketamine spray Spravato won approval and soared to blockbuster heights. But Spravato has an additional edge.
“Spravato also has that extra approval for acute suicidality, which might scoot patients toward Spravato sooner,” Wille said, while noting that this probably only happens in rare cases based on conversations she’s had with physicians about prescribing patterns.
COMP360 is also more complex to administer than the currently approved depression treatments, requiring multiple hours of in-clinic time with trained professionals.
To get payers on board, Compass is likely to lean on its treatment’s durability, Wille said. In September, Compass released new, longer-term phase 3 data for COMP360, touting its durability for patients on various dosing schedules after 52 weeks.
“Across the 52-week study period, participants experienced cumulative and sustained reductions in depressive symptoms,” the company said in a release.
While it is still unclear how often patients would be dosed with COMP360 if it’s approved, it’s unlikely to be more than a few times a year, Wille said, which could make payers more open to covering it.
“The idea of having a treatment for this chronic disorder that you may only need two or three times a year … that’s very attractive to patients. And it’s attractive to payers,” Wille said.
As these dynamics play out, Compass will be doing a lot of the “initial grunt work” for the wider pharma industry by navigating how to bring a classic psychedelic drug to market and get it to patients, Wille said. And that market is set to potentially expand in the coming years as companies like Definium Therapeutics and AtaiBeckley, which was recently acquired by Eli Lilly, advance their psychedelic-based candidates through the clinic for various psychiatric indications.
“What we’re learning from these psilocybin NDAs and the way the FDA responds and what we hear about payer coverage … is just going to be the building blocks toward potentially someday having a healthcare system that supports this type of treatment,” Wille said.